7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Privacy Policy
Close This Panel X
  • Latest News
  • Most Popular
View All | Scroll Down Scroll Up

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/17/2013

Company Name Symbol %Change
VIASAT INC VSAT
19.35%
OLD SECOND B OSBC
5.76%
GAMCO INVEST GBL
4.61%
CORNING INC GLW
4.47%
SYNCHRONOSS SNCR
4.23%

Zacks Rank #1 Strong Buys

Analyst Blog

Print
Share

Shire to Buy Lotus Tissue Repair

by Zacks Equity Research

January 10, 2013 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Shire plc ( SHPG - Snapshot Report ) recently announced its intention to acquire privately-held biotech company, Lotus Tissue Repair, Inc.

Lotus Tissue Repair is developing a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa (DEB).
Shire will pay an upfront fee for the acquisition along with certain contingent payments based on the achievement of certain safety and development milestones. Other financial details were not disclosed.
Shire’s Human Genetic Therapies business will take over the development of Lotus Tissue Repair’s lead candidate, a proprietary recombinant form of human collagen type VII (rC7), an intravenous protein replacement therapy for the treatment of DEB. We note that Shire already has an EB candidate, ABH001, in its pipeline. ABH001 is being developed as a dermal substitute therapy for the treatment of non-healing wounds in patients with EB.
Concurrent with this acquisition, Shire also stated that it expects to meet the general consensus earnings estimate of $6.69 – $6.70 in 2012 driven by a double digit growth in revenues.
The company’s leading drug in the key attention deficit hyperactivity disorder (ADHD) market, Vyvanse, represents significant commercial potential. Vyvanse is being developed for new indications such as major depressive disorder, binge eating, and negative symptoms of schizophrenia, all being in phase III studies.
Vyvanse and Intuniv both together account for 45% of the total market growth in the US ADHD market. Vyvanse should gain approval in Europe (under the trade name Elvanse) soon given the positive outcome from the European Decentralised Procedure (DCP) in Dec 2012. According to the company, the European market is currently worth $500 million.
However, Shire faces stiff competition from the likes of Johnson & Johnson ( JNJ - Analyst Report ) and Novartis ( NVS - Snapshot Report ) in the key ADHD market.
We currently have a Neutral recommendation on Shire which carries a Zacks Rank #3 (Hold). Right now, pharma stock Novartis ( NVS - Snapshot Report ) looks more attractive with a Zacks Rank #2 (Buy).

Read the full Snapshot Report on SHPG

Read the full Snapshot Report on NVS

Read the full Analyst Report on JNJ

Email Print Share Rate Pos Rate Neg

Disclosure / Disclaimer Link
Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.
Quick Links

Services

My Account

Resources

Client Support

Follow Us

Facebook

Twitter

Linkedin

RSS

You Tube

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.

Copyright 2013 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.